Amgros Awards DKK 13.1 Million Metreleptin Framework to Chiesi Pharma

Amgros I/S has awarded a DKK 13.1 million framework agreement for Metreleptin to Chiesi Pharma AB. The single-lot framework covers the supply of the orphan drug for the treatment of leptin deficiency and lipodystrophy to Danish hospital pharmacies, with the contract running from December 2026 to March 2030.

Introduction

Specialist medicines for rare diseases are essential for patients with specific medical conditions. Amgros, the Danish central purchasing body for pharmaceuticals, has awarded a framework for Metreleptin—an orphan drug used to treat leptin deficiency and lipodystrophy.

The framework, valued at up to DKK 13.1 million (approximately €1.76 million), has been awarded to Chiesi Pharma AB. The contract covers three strengths of Metreleptin (3 mg, 5.8 mg, and 11.3 mg) for Danish hospital pharmacies. The contract runs from December 2026 to March 2030, with two 12-month extension options.

This procurement ensures that Danish hospitals have access to this essential orphan drug for patients with rare metabolic conditions.

Why This Contract Matters

Metreleptin is an orphan drug used to treat leptin deficiency and lipodystrophy—rare conditions that require specialist treatment. This framework ensures the supply of this essential medicine to Danish hospital pharmacies.

This contract matters because it:

• Supports rare disease treatment: Ensures access to Metreleptin for patients with lipodystrophy and leptin deficiency
• Orphan drug: Metreleptin is an orphan drug with a small patient population
• Significant value: DKK 13.1 million framework
• Long-term supply: 3+ years with extension options
• Single supplier: Chiesi Pharma is the sole bidder
• Price-focused: Price-only evaluation (100%)
• Swedish supplier: Chiesi Pharma AB is based in Sweden

Contract Timeline

• Contract award notice published: 17 August 2026 (OJ S 157/2026)
• Previous notice referenced: 307778-2026
• Contract concluded: 14 August 2026
• Coverage start date: 1 December 2026
• Coverage end date: 31 March 2030

Contract Overview

Amgros conducted an open procedure for this procurement. The framework covers the supply of Metreleptin for Danish hospital pharmacies, with potential resale to the Faroe Islands and Greenland.

Key features include:

• Single lot: Metreleptin (three strengths)
• Duration: 1 December 2026 – 31 March 2030 (with 2 x 12-month extension options)
• Value: DKK 13,100,000
• Evaluation: Price only (100%)
• Framework type: Without reopening of competition
• Non-exclusive: Hospital pharmacies are not obligated to use the framework
• Winner: Chiesi Pharma AB

Key Contract Details

Detail	Information
Contracting authority	Amgros I/S
Winning bidder	Chiesi Pharma AB
Contract subject	Metreleptin (orphan drug) – CPV 33600000
Procedure type	Open procedure
Legal basis	EU Directive 2014/24/EU
Maximum value (DKK)	DKK 13,100,000.00 (approx. €1.76 million)
Awarded value (DKK)	DKK 7,770,000.00
Contract duration	1 Dec 2026 – 31 Mar 2030 (+ 2 x 12-month options)
Bids received	1
EU funding	None
Covered by GPA	Yes
Evaluation criteria	Price only (100%)
Subcontracting	No
Supplier size	SME

Project Scope

The framework covers the supply of Metreleptin for Danish hospital pharmacies:

Products Covered

• ATC Code: A16AA07
• Generic name: Metreleptin
• Dispensing form: Powder for injection solution
• Strengths:
  • 3 mg (99 units estimated)
  • 5.8 mg (742 units estimated)
  • 11.3 mg (99 units estimated)

Indications

• Leptin deficiency: Congenital or acquired leptin deficiency
• Lipodystrophy: Generalised lipodystrophy
• Orphan drug: Used for rare metabolic conditions

Delivery

• Delivery locations: Amgros warehouse, hospitals, and hospital pharmacies across Denmark
• Regions covered: All five Danish regions
• Potential resale: Faroe Islands and Greenland

Contract Features

• Non-exclusive: Hospital pharmacies are not obligated to use the framework
• No purchase obligation: Hospital pharmacies can source from other suppliers
• Pre- and post-agreement period options: Flexible ordering

About the Contracting Authority

Amgros I/S is a Danish joint procurement body (interessentskab) owned by the five Danish regions. Amgros is responsible for purchasing pharmaceuticals and medical equipment for the Danish hospital sector. As a central purchasing body, Amgros negotiates framework agreements that are available to hospital pharmacies across Denmark.

About the Winning Company

Chiesi Pharma AB is a Swedish pharmaceutical company based in Stockholm, part of the Chiesi Group, an international pharmaceutical company specialising in respiratory, rare disease, and specialist medicines. Chiesi has expertise in orphan drugs and rare disease treatments. The company's winning bid was the only tender received.

Procurement Analysis

• Procedure: An open procedure was used, allowing any interested economic operator to submit a tender.
• Competition: Only one bid was received, reflecting the specialist nature of orphan drugs like Metreleptin.
• Evaluation criteria: Price only (100%). This is standard for pharmaceutical procurement where quality is assured through regulatory approvals.
• Orphan drug market: The limited number of suppliers reflects the small patient population and specialist manufacturing requirements.
• Single supplier: Chiesi Pharma was the sole bidder.
• International participation: The winner is a Swedish company, demonstrating cross-border pharmaceutical supply.
• SME supplier: Chiesi Pharma AB is an SME.

Additional Procurement Facts

• The contract is covered by the WTO's Government Procurement Agreement (GPA).
• No EU funds were used for this procurement.
• The procurement was not accelerated.
• No dynamic purchasing system was used.
• Framework agreement without reopening of competition.
• Only one bid was received (from Chiesi Pharma).
• The bidder is an SME.
• No subcontracting was declared.
• Disputes or review requests fall to Klagenævnet for Udbud.
• Delivery locations include hospitals and hospital pharmacies across all Danish regions.

Market & Industry Perspective

The market for orphan drugs is characterised by a limited number of suppliers due to the small patient populations and complex manufacturing requirements. Metreleptin is a niche product with only a few suppliers globally.

Key trends in this market include:

• Orphan drug focus: Growing attention to rare disease treatments
• Limited competition: Orphan drugs often have few suppliers
• Price focus: Price-only evaluation drives competition where possible
• Centralised procurement: Amgros centralises procurement for efficiency
• Cross-border supply: Suppliers from across Europe compete

The single-bid outcome reflects the specialist nature of Metreleptin and the limited number of suppliers capable of manufacturing this orphan drug.

Economic Significance

At DKK 13.1 million, this framework represents a significant procurement for a specialist orphan drug. The contract ensures:

• Patient access: Patients with lipodystrophy and leptin deficiency can access treatment
• Supply security: Danish hospital pharmacies have a reliable supply
• Cost efficiency: Competitive procurement ensures value for money
• Regional coverage: All five Danish regions are covered

Future Procurement Opportunities

With the framework now in place, future opportunities include:

• Contract extensions: Up to 2 x 12-month extension options
• Re-tender: The framework will be re-tendered after 2030
• Other orphan drugs: Similar frameworks for other rare disease medicines
• Other Amgros tenders: Amgros conducts many pharmaceutical procurements

Opportunities for Suppliers

While this framework is awarded, future opportunities exist for pharmaceutical companies:

• Other Amgros tenders: Amgros conducts many other pharmaceutical procurements
• Other orphan drugs: Similar frameworks for other rare disease medicines
• Other European countries: Similar frameworks by other central purchasing bodies
• Re-tender: The framework will be re-tendered in the future

What Businesses Should Watch

• Amgros' future procurement notices for orphan drugs
• Other European central purchasing bodies' orphan drug tenders
• Emerging rare disease treatments
• Changes to Danish pharmaceutical regulations
• EU orphan drug regulations

DenmarkTenders Procurement Intelligence

This Metreleptin framework is a significant procurement for a specialist orphan drug. Several features stand out:

• Scale: DKK 13.1 million for a rare disease medicine
• Orphan drug: Specialist product with limited supplier base
• Price focus: Price-only evaluation (100%)
• Single bidder: Reflects the specialist nature of the product
• International supplier: Swedish company supplying the Danish market

For suppliers, this procurement highlights the importance of:

• Competitive pricing: Price is the sole criterion (100%)
• Regulatory compliance: Quality is assured through regulatory approvals
• European presence: Ability to supply across borders
• Orphan drug expertise: Specialist manufacturing and distribution capabilities

Supplier Takeaways

• Offer competitive pricing—price is the sole criterion (100%)
• Ensure regulatory compliance for pharmaceutical products
• Develop European presence to participate in cross-border tenders
• Build expertise in orphan drugs and rare disease treatments
• Monitor Amgros for future pharmaceutical opportunities
• Consider SME status as an advantage in this market

Key Takeaways

• Amgros awarded a DKK 13.1 million Metreleptin framework to Chiesi Pharma AB
• Single lot covering 3 strengths of Metreleptin (3 mg, 5.8 mg, 11.3 mg)
• Orphan drug for lipodystrophy and leptin deficiency
• Evaluation: Price only (100%)
• 1 bid received (Chiesi Pharma)
• Duration: 1 Dec 2026 – 31 Mar 2030 (+ 2 x 12-month options)
• Swedish supplier (SME)
• No EU funding used

Conclusion

This Metreleptin framework represents a significant procurement for an essential orphan drug for Danish hospital pharmacies. By awarding the contract to Chiesi Pharma AB, Amgros ensures that patients with leptin deficiency and lipodystrophy have access to this specialist treatment.

The single-bid outcome reflects the limited number of suppliers for orphan drugs, which are complex to manufacture and serve small patient populations. The price-only evaluation (100%) is standard for pharmaceutical procurement, where quality is assured through regulatory approvals.

As Amgros continues to conduct pharmaceutical procurements for the Danish hospital sector, further opportunities will arise for suppliers with competitive pricing and specialist capabilities.

Frequently Asked Questions

Q: What is Amgros?

Ans: A Danish joint procurement body (interessentskab) owned by the five Danish regions, responsible for purchasing pharmaceuticals for the hospital sector.

Q: What is the value of the framework?

Ans: DKK 13,100,000 (approximately €1.76 million).

Q: Who won the contract?

Ans: Chiesi Pharma AB, a Swedish pharmaceutical company.

Q: What is Metreleptin?

Ans: An orphan drug used to treat leptin deficiency and lipodystrophy.

Q: What were the evaluation criteria?

Ans: Price only (100%).

Q: How long is the contract?

Ans: 1 December 2026 – 31 March 2030 (with 2 x 12-month extension options).

Q: How many bids were received?

Ans: Only one bid was received.

Q: Is this contract funded by the EU?

Ans: No, the procurement is not financed with EU funds.

Source: EU Official Journal, Contract Award Notice 566842-2026, OJ S 157/2026, published 17 August 2026.